Table 1.
Clinical and molecular characteristics.
| All tumors (n = 160) | TERT promoter | ATRX expression | P53 expression | PDGFRA amplification | CDKN2A deletion | CDK4 amplification | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| wt (n = 131) | mut (n = 26) | Positive (n = 39) | Negative (n = 109) | Negative (n = 78) | Positive (n = 78) | Negative (n = 130) | Positive (n = 30) | Negative (n = 136) | Positive (n = 24) | negative (n = 131) | Positive (n = 29) | ||
| Age (mean/median) | 40.5/40.0 | 40.1/39.0 | 42.8/45.0 | 39.0/38.0 | 40.5/40.0 | 40.5/39.5 | 40.9/41.0 | 39.5/39.0 | 44.8/44.5 | 40.6/40.5 | 39.9/39.0 | 41.2/41.0 | 37.6/39.0 |
| Gender | |||||||||||||
| Male | 86 (53.8%) | 66 (78.6%) | 18 (21.4%) | 24 (30.8%) | 54 (69.2%) | 40 (48.2%) | 43 (51.8%) | 70 (81.4%) | 16 (18.6%) | 73 (84.9%) | 13 (15.1%) | 70 (81.4%) | 16 (18.6%) |
| Female | 74 (46.3%) | 65 (89.0%) | 8 (11.0%) | 15 (21.4%) | 55 (78.6%) | 38 (52.1%) | 35 (47.9%) | 60 (81.1%) | 14 (18.9%) | 63 (85.1%) | 11 (14.9%) | 61 (82.4%) | 13 (17.6%) |
| Histological grade | |||||||||||||
| Diffuse astrocytoma (Grade II) | 106 (66.3%) | 88 (85.4%) | 15 (14.6%) | 27 (26.7%) | 74 (73.3%) | 46 (44.7%) | 57 (55.3%) | 93 (87.7%) | 13 (12.3%) | 93 (87.7%) | 13 (12.3%) | 87 (82.1%) | 19 (17.9%) |
| Anaplastic astrocytoma (Grade III) | 54 (33.8%) | 43 (79.6%) | 11 (20.4%) | 12 (25.5%) | 35 (74.5%) | 32 (60.4%) | 21 (39.6%) | 37 (68.5%) | 17 (31.5%) | 43 (79.6%) | 11 (20.4%) | 44 (81.5%) | 10 (18.5%) |
| Location | |||||||||||||
| Cerebellum | 1 (0.6%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) |
| Midline | 17 (10.6%) | 14 (82.4%) | 3 (17.6%) | 3 (20.0%) | 12 (80.0%) | 10 (58.8%) | 7 (41.2%) | 15 (88.2%) | 2 (11.8%) | 13 (76.5%) | 4 (23.5%) | 13 (76.5%) | 4 (23.5%) |
| Hemisphere | 141 (88.1%) | 116 (84.1%) | 22 (15.9%) | 35 (26.7%) | 96 (73.3%) | 66 (48.2%) | 71 (51.8%) | 113 (80.1%) | 28 (19.9%) | 123 (87.2%) | 18 (12.8%) | 116 (82.3%) | 25 (17.7%) |
| Not available | 1 (0.6%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) |
| Extent of resection | |||||||||||||
| Total resection | 126 (78.8%) | 103 (83.7%) | 20 (16.3%) | 32 (27.6%) | 84 (72.4%) | 59 (48.4%) | 63 (51.6%) | 101 (80.2%) | 25 (19.8%) | 111 (88.1%) | 15 (11.9%) | 102 (81.0%) | 24 (19.0%) |
| Non‐total resection | 33 (20.6%) | 28 (84.8%) | 5 (15.2%) | 6 (19.4%) | 25 (80.6%) | 18 (54.5%) | 15 (45.5%) | 28 (84.8%) | 5 (15.2%) | 25 (75.8%) | 8 (24.2%) | 28 (84.8%) | 5 (15.2%) |
| Not available | 1 (0.6%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) |
| Adjuvant therapy | |||||||||||||
| No adjuvant therapy | 15 (9.4%) | 12 (80.0%) | 3 (20.0%) | 5 (35.7%) | 9 (64.3%) | 10 (66.7%) | 5 (33.3%) | 10 (66.7%) | 5 (33.3%) | 14 (93.3%) | 1 (6.7%) | 11 (73.3%) | 4 (26.7%) |
| Chemotherapy only | 7 (4.4%) | 6 (85.7%) | 1 (14.3%) | 1 (14.3%) | 6 (85.7%) | 3 (42.9%) | 4 (57.1%) | 7 (100.0%) | 0 (0.0%) | 6 (85.7%) | 1 (14.3%) | 7 (100.0%) | 0 (0.0%) |
| Radiotherapy only | 7 (4.4%) | 7 (100.0%) | 0 (0.0%) | 3 (42.9%) | 4 (57.1%) | 2 (28.6%) | 5 (71.4%) | 5 (71.4%) | 2 (28.6%) | 7 (100.0%) | 0 (0.0%) | 6 (85.7%) | 1 (14.3%) |
| Chemo‐radiotherapy | 129 (80.6%) | 105 (83.3%) | 21 (16.7%) | 29 (24.6%) | 89 (75.4%) | 61 (48.8%) | 64 (51.2%) | 107 (82.9%) | 22 (17.1%) | 108 (83.7%) | 21 (16.3%) | 105 (81.4%) | 24 (18.6%) |
| Not available | 2 (1.3%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) | 0 (0.0%) |
Abbreviations: mut = mutant; n = number of cases; wt = wild type.